News | Cath Lab | November 10, 2016

Study Concludes Very Early Percutaneous Coronary Intervention Following Fibrinolysis Safe

The Minneapolis Heart Institute Foundation conducted a 13-year study to determine the safety and feasibility of using PCI earlier in STEMI patients

fibrinolysis, FL, STEMI patients, ACCF/AHA guidelines, Minneapolis Heart Institute, AHA Scientific Sessions 2016

November 10, 2016 — Current ACCF/AHA guidelines recommend fibrinolysis (FL) as the preferred reperfusion strategy for ST-segment elevation myocardial infarction (STEMI) patients with expected delays of > 120 minutes from first medical contact to percutaneous coronary intervention (PCI). The guidelines recommend this be followed by transfer to a PCI center with angiography/PCI within 3-24 hours. However, assessment of reperfusion prior to angiography may not be accurate based on clinical and electrocardiogram (ECG) criteria alone. Recent data suggested increased recurrent ischemic events within the first 24 hours. The aim of this study, which was conducted from 2003-2015, was to assess the safety of very early PCI (< 3 hours) following FL.

The Minneapolis Heart Institute Level 1 MI program is a regional STEMI system with a standardized protocol where patients transferred from spoke hospitals with expected delays of > 120 minutes to PCI receive a pharmacoinvasive (PI) therapy with transfer for immediate PCI. Prospective registry data from the Level 1 database were analyzed to compare clinical outcomes related to the timing of PCI following FL, stratified into groups of <60, 61-90, 91-120, 121-180 and >180 minutes. Patients transferred for PCI alone were available for comparison.

From 2003 to 2015, 3,453 STEMI patients were transferred from spoke hospitals for immediate PCI, including 867 receiving FL. Pre-PCI IMI 2/3 flow occurred in 71 percent, but decreased with longer time from FL to PCI. The majority of PI patients underwent PCI 61-90 (47 percent) or 91-120 (28 percent) minutes post-FL. There were no significant differences in mortality, bleeding, reinfarction or stroke related to timing of PCI between these five groups. These results indicate that early PCI (< 3 hours) after FL is safe and may decrease recurrent ischemia. Therefore, delaying PCI for 3-24 hours following FL may not be necessary.

A poster presentation on the study will be given at the American Heart Association Scientific Sessions, Nov. 12-16, in New Orleans.

For more information: www.mplsheart.org

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init